Role of Quantitative HBsAg Testing in Clinical Practice for People With CHB

Should quantitative HBsAg testing be used routinely in clinical practice for patients living with chronic hepatitis B?

In this episode, Tatyana Kushner, MD, MSCE, discusses the role of quantitative hepatitis B surface antigen testing in people living with chronic hepatitis B, including:

• Determination of inactive carrier status
• Prediction of liver fibrosis/cirrhosis
• Prediction of hepatocellular carcinoma development
• Monitoring response to treatment, including future HBV treatments in the development pipeline
• Prediction of HBsAg loss

Joining her for the panel discussion are Ira M. Jacobson, MD, and Paul Y. Kwo, MD.

Presenters:

Ira M. Jacobson, MD
Professor of Medicine
Director of Hepatology
NYU Langone Health
New York, New York

Tatyana Kushner, MD, MSCE
Associate Professor
Division of Liver Diseases
Icahn School of Medicine at 
Mount Sinai
New York, New York

Paul Y. Kwo, MD
Professor of Medicine 
Director of Hepatology 
Stanford University School of Medicine
Palo Alto, California

Link to the full program: 
https://bit.ly/3R1PMi4

Link to the slides: 
https://bit.ly/3N5Fpsm

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.